<H1>Chapter DOI: 10.1007/978-1-60327-829-4_7<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>38</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>38</td></tr><tr><td>BibStructured Count</td><td width="10%">38</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>24</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_7</td><td>BibArticle</td><td>Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1998;173:534&#8211;40.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(05)80067-1>10.1016/S0006-291X(05)80067-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_7</td><td>BibArticle</td><td>Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149&#8211;53.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_7</td><td>BibArticle</td><td>Kokontsi J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54:1566&#8211;73.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4_7</td><td>BibArticle</td><td>Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242&#8211;51.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6690684>10.1038/sj.bjc.6690684</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_7</td><td>BibArticle</td><td>Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_7</td><td>BibArticle</td><td>Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 2000;60:5825&#8211;31.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7_7</td><td>BibArticle</td><td>Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997;57:4511&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_7</td><td>BibArticle</td><td>Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 2008;68:5460&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-08-0955>10.1158/0008-5472.CAN-08-0955</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_7</td><td>BibArticle</td><td>Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced receptor function. Am J Pathol 2003;162:233&#8211;41.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)63814-X>10.1016/S0002-9440(10)63814-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_7</td><td>BibArticle</td><td>Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005;65:5965&#8211;73.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-2837>10.1158/0008-5472.CAN-04-2837</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_7</td><td>BibArticle</td><td>Steers WD. 5alpha-reductase activity in the prostate. Urology 2001;58:17&#8211;24.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(01)01299-7>10.1016/S0090-4295(01)01299-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_7</td><td>BibArticle</td><td>Cai LQ, Zhu YS, Katz MD, Herrera C, Baez J, de Fillo-Ricart M, et al. 5-alpha-reductase-2 gene mutations in the Dominican republic. Clin Endocrinol Metab. 199;81:1730&#8211;5.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1210/jcem.81.5.8626825>10.1210/jcem.81.5.8626825</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR13_7</td><td>BibArticle</td><td>Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507&#8211;11.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_7</td><td>BibArticle</td><td>O&#8217;Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, H&#246;fner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003;92:262&#8211;6.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.2003.04310.x>10.1046/j.1464-410X.2003.04310.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_7</td><td>BibArticle</td><td>Titus MA, Gregory CW, Ford 3rd OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365&#8211;71.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-0738>10.1158/1078-0432.CCR-04-0738</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_7</td><td>BibArticle</td><td>Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0525>10.1158/1078-0432.CCR-05-0525</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_7</td><td>BibArticle</td><td>Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147&#8211;51.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.08.155>10.1016/j.juro.2007.08.155</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_7</td><td>BibArticle</td><td>Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res 2003;9:1815&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_7</td><td>BibArticle</td><td>Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068&#8211;72.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_7</td><td>BibArticle</td><td>Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 2000;60:3623&#8211;30.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_7</td><td>BibArticle</td><td>Makridakis N, Akalu A, Reichardt JK. Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 2004;23:7399&#8211;405.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1207922>10.1038/sj.onc.1207922</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_7</td><td>BibArticle</td><td>Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis-sense subtitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles. USA Lancet 1999;354:975&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(98)11282-5>10.1016/S0140-6736(98)11282-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_7</td><td>BibArticle</td><td>Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, et al. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. J Urol 2008;180:367&#8211;72.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2008.02.036>10.1016/j.juro.2008.02.036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_7</td><td>BibArticle</td><td>Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12:4072&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-0184>10.1158/1078-0432.CCR-06-0184</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_7</td><td>BibArticle</td><td>Schmidt LJ, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5-alpha-reductase inhibitor dutasteride. J Androl 2004;25:944&#8211;53.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/j.1939-4640.2004.tb03166.x>10.1002/j.1939-4640.2004.tb03166.x</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR26_7</td><td>BibArticle</td><td>Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, et al. Enhancement of intermittent androgen ablation by &#8220;off-cycle&#8221; maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 2006;66:495&#8211;502.</td><td><a href=http://dx.doi.org/10.1002/pros.20297>10.1002/pros.20297</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_7</td><td>BibArticle</td><td>Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama A. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998;82:531&#8211;7.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0142(19980201)82:3&lt;531::AID-CNCR15&gt;3.0.CO;2-2>10.1002/(SICI)1097-0142(19980201)82:3&lt;531::AID-CNCR15&gt;3.0.CO;2-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_7</td><td>BibArticle</td><td>Presti JC, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:1201.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29_7</td><td>BibArticle</td><td>Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)80021-1>10.1016/S0090-4295(99)80021-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_7</td><td>BibArticle</td><td>Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57:714&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31_7</td><td>BibArticle</td><td>Habib FK, Ross M, Ho CK, Lyons V, Chapman K.<Emphasis Type="Italic">Serenoa repens</Emphasis>(Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 2005;114:190&#8211;4.</td><td><a href=http://dx.doi.org/10.1002/ijc.20701>10.1002/ijc.20701</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_7</td><td>BibArticle</td><td>Klotz L, Saad F, PCPT-MTOPS Consensus Panel. PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Can Urol Assoc J 2007;1:17&#8211;21.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_7</td><td>BibArticle</td><td>Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375&#8211;83.</td><td><a href=http://dx.doi.org/10.1093/jnci/djm117>10.1093/jnci/djm117</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_7</td><td>BibArticle</td><td>Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman Jr CA, et al. Implementation of the prostate cancer prevention trial control. Clin Trials 2004;25:203&#8211;22.</td><td><a href=http://dx.doi.org/10.1016/j.cct.2003.11.007>10.1016/j.cct.2003.11.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_7</td><td>BibArticle</td><td>Gommella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29&#8211;32.</td><td><a href=http://dx.doi.org/10.1097/00042307-200501000-00007>10.1097/00042307-200501000-00007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_7</td><td>BibArticle</td><td>McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998;338:557&#8211;63.</td><td><a href=http://dx.doi.org/10.1056/NEJM199802263380901>10.1056/NEJM199802263380901</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_7</td><td>BibArticle</td><td>Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006;68:116&#8211;20.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2006.01.061>10.1016/j.urology.2006.01.061</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_7</td><td>BibArticle</td><td>Rubin MA, Kantoff PW. Effect of finasteride on risk of prostate cancer: how little we really know. J Cell Biochem 2004;91:478&#8211;82.</td><td><a href=http://dx.doi.org/10.1002/jcb.10787>10.1002/jcb.10787</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>